Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.85 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.58 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.49 |
| ▸ | AKT2 | P31751 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7290518 | 0.89 | HRH4 (0.70) | HRH4PDPK1GDACDK2DPP4 | |
| SCHEMBL6823677 | 0.80 | HRH4 (0.62) | HRH4PDPK1GDACDK2DPP4 | |
| SCHEMBL1030947 | 0.80 | HRH4 (0.61) | HRH4CDK2DPP4PDGFRBADORA1 | |
| SCHEMBL3773144 | 0.78 | HRH4 (0.56) | HRH4PDPK1GDACDK2DPP4 | |
| SCHEMBL7664448 | 0.76 | PDGFRB (0.55) | HRH4PDGFRBHTTLMNACDK1 | |
| 2,6-Diaminopurine SCHEMBL24053 | 0.74 | PDPK1 (1.00) | HRH4PDPK1GDACDK2DPP4 | |
| SCHEMBL17364332 | 0.73 | DPP4 (0.51) | HRH4PDPK1GDACDK2DPP4 | |
| SCHEMBL7298815 | 0.73 | HRH4 (0.70) | HRH4HTTMAP3K5MAPK1TP53 | |
| SCHEMBL3780112 | 0.73 | HRH4 (0.51) | HRH4PDPK1GDACDK2DPP4 | |
| SCHEMBL6755685 | 0.73 | HTT (0.86) | HRH4PDPK1HTTMAP3K5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11965209-B2 | Method for obtaining structural information concerning an encoded molecule and method for selecting compounds | NUEVOLUTION A/S (DK) | 2024-04-23 | — | — | US | claimed |
| US-20220205027-A1 | METHOD FOR OBTAINING STRUCTURAL INFORMATION CONCERNING AN ENCODED MOLECULE AND METHOD FOR SELECTING COMPOUNDS | NUEVOLUTION A/S (DK) | 2022-06-30 | — | — | US | claimed |
| EP-3013958-B1 | GLUCAN-ENCAPSULATED SIRNA FOR TREATING TYPE 2 DIABETES MELLITUS | US HEALTH (US) | 2019-12-25 | — | — | EP | claimed |
| US-10077446-B2 | Glucan-encapsulated siRNA for treating type 2 diabetes mellitus | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2018-09-18 | — | — | US | claimed |
| US-9885035-B2 | Method for the synthesis of a bifunctional complex | NUEVOLUTION A/S (DK) | 2018-02-06 | — | — | US | claimed |
| US-20160138028-A1 | GLUCAN-ENCAPSULATED SIRNA FOR TREATING TYPE 2 DIABETES MELLITUS | UNIVERSITY OF MASSACHUSETTS | 2016-05-19 | — | — | US | claimed |
| EP-3013958-A1 | GLUCAN-ENCAPSULATED SIRNA FOR TREATING TYPE 2 DIABETES MELLITUS | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2016-05-04 | — | — | EP | claimed |
| WO-2014210041-A1 | GLUCAN-ENCAPSULATED SIRNA FOR TREATING TYPE 2 DIABETES MELLITUS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICE (US) | 2014-12-31 | — | — | WO | claimed |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-07-23 | — | — | US | disclosed |
| US-11963968-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240115678-A1 | PERSONALIZED MULTIDISCIPLINARY CANCER THERAPY | VELTMEYER JAMES (US) | 2024-04-11 | — | — | US | disclosed |
| EP-3204032-B1 | CHIMERIC MOLECULE COMPRISING CRISPR/CAS OR CAS9 NUCLEASE AND AT LEAST ONE GUIDE RNA TARGETING PMCA2 GENE LOCUS AND FUSED, COMPLEXED OR LINKED TO AN ANIONIC FLUORESCENT PROTEIN, AND ITS USE IN THE TREATMENT OF DEAFNESS OR DISORDERS THEREOF | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| US-20240067963-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIAC DISEASES | JAAN BIOTHERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2007120166-A2 | MINIATURIZED IN VITRO PROTEIN EXPRESSION ARRAY | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070212311-A1 | Recombinant Alkalinizing Bacteria | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20060057622-A1 | Low cycle amplification of RNA molecules | UNIVERSITY OF FLORIDA (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2005052145-A2 | RECOMBINANT ALKALIIZING BACTERIA | UNIVERSITY OF FLORIDA (US) | 2005-06-09 | — | — | WO | disclosed |
| US-6639059-B1 | Novel synthesis strategy comprising novel key intermediate, (2.2.1)bicyclo nucleosides are produced at least two steps shorter than any previously known strategy; 3-O-aryl-4-C-hydroxymethyl-1,2-O-isopropylidene-alpha-D-ribofuranose | EXIQON A/S (DK) | 2003-10-28 | — | — | US | disclosed |
| US-20030198960-A1 | Signal amplifying targeted reporters for biological and chemical sensor applications | INTEGRATED NANOSYSTEMS, INC. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | HRH4 1693/4885PDPK1 2970/4885GDA 4433/4885 |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | ASGR1, HAVCR2, SIGLEC7 | HRH4 1323/4885PDPK1 3426/4885GDA 439/4885 |
| US-11963968-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | HRH4 3263/4885PDPK1 192/4885GDA 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.